RU2284327C2 - Имидазоло-5-ил-2-анилинопиримидины как агенты для ингибирования пролиферации клеток, способ их получения (варианты), применение, фармацевтическая композиция, способ продуцирования - Google Patents

Имидазоло-5-ил-2-анилинопиримидины как агенты для ингибирования пролиферации клеток, способ их получения (варианты), применение, фармацевтическая композиция, способ продуцирования Download PDF

Info

Publication number
RU2284327C2
RU2284327C2 RU2003109612/04A RU2003109612A RU2284327C2 RU 2284327 C2 RU2284327 C2 RU 2284327C2 RU 2003109612/04 A RU2003109612/04 A RU 2003109612/04A RU 2003109612 A RU2003109612 A RU 2003109612A RU 2284327 C2 RU2284327 C2 RU 2284327C2
Authority
RU
Russia
Prior art keywords
sulfamoyl
alkyl
formula
compound
pharmaceutically acceptable
Prior art date
Application number
RU2003109612/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2003109612A (ru
Inventor
Глори Анн БРО (GB)
Глория Анн БРО
Николас Джон НЬЮКОМ (GB)
Николас Джон НЬЮКОМ
Эндрю Питер ТОМАС (GB)
Эндрю Питер Томас
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9898838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2284327(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2003109612A publication Critical patent/RU2003109612A/ru
Application granted granted Critical
Publication of RU2284327C2 publication Critical patent/RU2284327C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
RU2003109612/04A 2000-09-05 2001-08-30 Имидазоло-5-ил-2-анилинопиримидины как агенты для ингибирования пролиферации клеток, способ их получения (варианты), применение, фармацевтическая композиция, способ продуцирования RU2284327C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0021726.5A GB0021726D0 (en) 2000-09-05 2000-09-05 Chemical compounds
GB0021726.5 2000-09-05

Publications (2)

Publication Number Publication Date
RU2003109612A RU2003109612A (ru) 2004-12-10
RU2284327C2 true RU2284327C2 (ru) 2006-09-27

Family

ID=9898838

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003109612/04A RU2284327C2 (ru) 2000-09-05 2001-08-30 Имидазоло-5-ил-2-анилинопиримидины как агенты для ингибирования пролиферации клеток, способ их получения (варианты), применение, фармацевтическая композиция, способ продуцирования

Country Status (32)

Country Link
US (2) US6969714B2 (https=)
EP (1) EP1351958B1 (https=)
JP (1) JP3523641B2 (https=)
KR (1) KR100802368B1 (https=)
CN (1) CN1269813C (https=)
AR (1) AR033836A1 (https=)
AT (1) ATE269327T1 (https=)
AU (2) AU8419201A (https=)
BG (1) BG107579A (https=)
BR (1) BR0113496A (https=)
CA (1) CA2417148C (https=)
CZ (1) CZ2003617A3 (https=)
DE (1) DE60103935T2 (https=)
DK (1) DK1351958T3 (https=)
EE (1) EE05430B1 (https=)
ES (1) ES2221904T3 (https=)
GB (1) GB0021726D0 (https=)
HU (1) HUP0302922A3 (https=)
IL (1) IL154292A0 (https=)
IS (1) IS2055B (https=)
MX (1) MXPA03001511A (https=)
MY (1) MY127126A (https=)
NO (1) NO324059B1 (https=)
NZ (1) NZ523787A (https=)
PL (1) PL360627A1 (https=)
PT (1) PT1351958E (https=)
RU (1) RU2284327C2 (https=)
SK (1) SK287277B6 (https=)
TW (1) TWI242559B (https=)
UA (1) UA74206C2 (https=)
WO (1) WO2002020512A1 (https=)
ZA (1) ZA200300612B (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
GB0205688D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GB0402277D0 (en) * 2004-02-03 2004-03-10 Astrazeneca Ab Chemical compounds
MX2007004488A (es) * 2004-10-13 2007-09-11 Wyeth Corp Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos.
CN101083996A (zh) * 2004-10-28 2007-12-05 Irm责任有限公司 作为hedgehog途径调节剂的化合物和组合物
NZ555474A (en) * 2004-12-17 2010-10-29 Astrazeneca Ab 4-(4-(imidazol-4-yl) pyrimidin-2-ylamino) benzamides as CDK inhibitors
CN1939910A (zh) * 2004-12-31 2007-04-04 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
GB0504753D0 (en) * 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
MX2008001428A (es) * 2005-07-30 2008-04-04 Astrazeneca Ab Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
WO2007036732A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
UY29827A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
CN101321531A (zh) * 2005-10-03 2008-12-10 阿斯利康(瑞典)有限公司 嘧啶衍生物在制备用于预防和/或治疗阿尔茨海默病的药物中的用途
JP2009534365A (ja) * 2006-04-21 2009-09-24 アストラゼネカ アクチボラグ Ａｄｇ受容体修飾物質として有用なスルホンアミド化合物
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
DE602007009535D1 (de) 2006-06-21 2010-11-11 Astrazeneca Ab Chemische verbindungen
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
TW200815417A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds II
JP2011518769A (ja) * 2008-03-14 2011-06-30 ビーエーエスエフ ソシエタス・ヨーロピア 殺菌剤として使用するための置換ピラジニルメチルスルホンアミド
JP5640005B2 (ja) * 2008-07-14 2014-12-10 ギリアード サイエンシーズ， インコーポレイテッド Ｈｄａｃおよび／またはｃｄｋ阻害剤としてのイミダゾシルピリジン化合物
CN101503402B (zh) * 2009-03-10 2014-06-25 沈阳药科大学 2-苯胺嘧啶衍生物及其制备和用途
JP2012524063A (ja) 2009-04-15 2012-10-11 アストラゼネカ・アクチエボラーグ アルツハイマー病などのグリコーゲンシンターゼキナーゼ３関連障害の治療に有用なイミダゾール置換ピリミジン
PT2576541T (pt) 2010-06-04 2016-07-08 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
HRP20172006T1 (hr) 2010-11-10 2018-02-09 Genentech, Inc. Derivati pirazol-aminopiridina kao lrrk2-modulatori
CN106928192B (zh) * 2015-12-29 2020-11-13 中国科学院广州生物医药与健康研究院 一种嘧啶类化合物及其制备方法和应用
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
TW202115024A (zh) 2019-08-14 2021-04-16 美商英塞特公司 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
KR20230127228A (ko) * 2020-11-27 2023-08-31 올오리온 테라퓨틱스 인크. 아미노헤테로아릴 키나아제 억제제
US20240287040A1 (en) * 2021-06-16 2024-08-29 Blueprint Medicines Corporation Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CN113999210B (zh) * 2021-12-03 2023-05-23 郑州大学第一附属医院 一组2-苯氨基-4-三氮唑基嘧啶类衍生物及其应用
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN116751167B (zh) * 2023-07-03 2025-09-23 苏州诚和医药化学有限公司 一种(e)-4-(1-苄基-2-甲基-1h-咪唑-5-基)-3-(乙氧基酰基)丁-3-烯酸的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859041A (en) * 1996-06-10 1999-01-12 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
WO1999032121A1 (en) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
RU2140918C1 (ru) * 1993-06-16 1999-11-10 Смитклайн Бичам Корпорейшн Три-замещенные имидазолы, обладающие терапевтическими свойствами, способ получения, фармацевтическая композиция, способ лечения
WO2000026209A1 (en) * 1998-11-03 2000-05-11 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659363A (en) 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
US4946956A (en) 1988-09-21 1990-08-07 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US4983608A (en) * 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
WO1994007890A1 (fr) * 1992-10-05 1994-04-14 Ube Industries, Ltd. Compose pyrimidine
KR100330553B1 (ko) 1993-10-01 2002-11-27 노파르티스 아게 약물학적활성피리딘유도체및그의제조방법
JPH08503971A (ja) 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト ピリミジンアミン誘導体及びその調製のための方法
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
WO1995009851A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
US5494998A (en) 1994-11-14 1996-02-27 Akzo Nobel N.V. Polymerization of carbon monoxide and ethylene using catalyst containing non-coordinating, non-acidic anion
ATE251141T1 (de) 1995-03-10 2003-10-15 Berlex Lab Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JP2000507558A (ja) 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
WO1997040017A2 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
WO1998016230A1 (en) 1996-10-17 1998-04-23 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
DE19710435A1 (de) 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
KR100704059B1 (ko) 1997-06-12 2007-04-05 롱프랑 로라 리미티드 이미다졸릴-사이클릭 아세탈
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
WO1999018096A1 (en) 1997-10-02 1999-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP1021173A1 (en) 1997-10-10 2000-07-26 Imperial College Innovations Limited Use of csaid?tm compounds for the management of uterine contractions
AU1507199A (en) 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
BR9908004A (pt) 1998-02-17 2001-12-18 Tularik Inc Composto, composição e método para prevençãoou supressão de uma infecção viral
CZ299380B6 (cs) 1998-03-27 2008-07-09 Janssen Pharmaceutica N. V. Pyrimidinová sloucenina, použití této slouceniny pro prípravu léciva, farmaceutický prostredek tutoslouceninu obsahující, zpusob prípravy tohoto prostredku a uvedené slouceniny a kombinace a produktuvedenou slouceninu obsahující
GB9806739D0 (en) 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
US6632820B1 (en) 1998-08-29 2003-10-14 Astrazeneca Ab Pyrimidine compounds
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
CA2344262A1 (en) 1998-09-18 2000-03-30 Basf Aktiengesellschaft 4-aminopyrrolopyrimidines as kinase inhibitors
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6627633B2 (en) 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
ATE311385T1 (de) 1999-10-27 2005-12-15 Novartis Pharma Gmbh Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
TR200201364T2 (tr) * 1999-11-22 2002-10-21 Smithkline Beecham P. L. C. Yeni bileşikler.
CA2394727A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
EP1257546A1 (en) 2000-02-17 2002-11-20 Amgen Inc. Kinase inhibitors
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
WO2003040131A1 (en) * 2001-11-07 2003-05-15 F. Hoffmann-La Roche Ag Aminopyrimidines and pyridines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2140918C1 (ru) * 1993-06-16 1999-11-10 Смитклайн Бичам Корпорейшн Три-замещенные имидазолы, обладающие терапевтическими свойствами, способ получения, фармацевтическая композиция, способ лечения
US5859041A (en) * 1996-06-10 1999-01-12 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
WO1999032121A1 (en) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
WO2000026209A1 (en) * 1998-11-03 2000-05-11 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles

Also Published As

Publication number Publication date
GB0021726D0 (en) 2000-10-18
SK287277B6 (sk) 2010-05-07
NO20031006L (no) 2003-03-04
NZ523787A (en) 2004-09-24
TWI242559B (en) 2005-11-01
ATE269327T1 (de) 2004-07-15
UA74206C2 (uk) 2005-11-15
PT1351958E (pt) 2004-09-30
EP1351958A1 (en) 2003-10-15
CA2417148A1 (en) 2002-03-14
SK2412003A3 (en) 2003-09-11
JP3523641B2 (ja) 2004-04-26
DE60103935D1 (de) 2004-07-22
CA2417148C (en) 2010-09-21
PL360627A1 (en) 2004-09-20
KR100802368B1 (ko) 2008-02-13
HUP0302922A2 (hu) 2003-12-29
NO324059B1 (no) 2007-08-06
WO2002020512A1 (en) 2002-03-14
AR033836A1 (es) 2004-01-07
ES2221904T3 (es) 2005-01-16
US20060004033A1 (en) 2006-01-05
KR20030027109A (ko) 2003-04-03
ZA200300612B (en) 2004-04-22
MXPA03001511A (es) 2003-06-09
AU2001284192B2 (en) 2006-10-26
US6969714B2 (en) 2005-11-29
US20040014776A1 (en) 2004-01-22
WO2002020512A9 (en) 2004-05-06
IL154292A0 (en) 2003-09-17
BR0113496A (pt) 2003-07-01
AU8419201A (en) 2002-03-22
CZ2003617A3 (cs) 2003-06-18
IS2055B (is) 2005-10-14
CN1269813C (zh) 2006-08-16
EP1351958B1 (en) 2004-06-16
EE05430B1 (et) 2011-06-15
HK1057553A1 (en) 2004-04-08
IS6715A (is) 2003-02-12
HUP0302922A3 (en) 2007-02-28
CN1452620A (zh) 2003-10-29
BG107579A (bg) 2003-10-31
EE200300088A (et) 2005-02-15
DE60103935T2 (de) 2005-07-21
DK1351958T3 (da) 2004-09-06
MY127126A (en) 2006-11-30
JP2004508365A (ja) 2004-03-18
NO20031006D0 (no) 2003-03-04

Similar Documents

Publication Publication Date Title
RU2284327C2 (ru) Имидазоло-5-ил-2-анилинопиримидины как агенты для ингибирования пролиферации клеток, способ их получения (варианты), применение, фармацевтическая композиция, способ продуцирования
RU2299201C2 (ru) Производные пиримидина, способ их получения (варианты), фармацевтические композиции (варианты) и способ ингибирования
RU2248976C2 (ru) Имидазо[1,2-а]пиридиновые и пиразол[2,3-а]пиридиновые производные
JP3569524B1 (ja) 化合物
US20090099160A1 (en) 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
AU2001284192A1 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
JP2006528962A (ja) ２−アニリノ−４−（イミダゾール−５−イル）−ピリミジン誘導体、および、ｃｄｋ（ｃｄｋ２）阻害剤としてのそれらの使用
JP4433797B2 (ja) ピリミジン化合物
HK1057553B (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120831